tradingkey.logo

Emergent BioSolutions Inc

EBS
查看詳細走勢圖
12.430USD
-0.200-1.58%
收盤 12/26, 16:00美東報價延遲15分鐘
655.06M總市值
8.75本益比TTM

Emergent BioSolutions Inc

12.430
-0.200-1.58%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.58%

5天

+0.08%

1月

+12.49%

6月

+95.75%

今年開始到現在

+30.02%

1年

+50.30%

查看詳細走勢圖

TradingKey Emergent BioSolutions Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

Emergent BioSolutions Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名53/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價13.50。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Emergent BioSolutions Inc評分

相關信息

行業排名
53 / 158
全市場排名
134 / 4563
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 2 分析師
買入
評級
13.500
目標均價
+13.73%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Emergent BioSolutions Inc亮點

亮點風險
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
估值高估
公司最新PE估值8.75,處於3年歷史高位
機構加倉
最新機構持股39.86M股,環比增加0.32%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉17.08K股

Emergent BioSolutions Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Emergent BioSolutions Inc簡介

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
公司代碼EBS
公司Emergent BioSolutions Inc
CEOPapa (Joseph C)
網址https://emergentbiosolutions.com/

常見問題

Emergent BioSolutions Inc(EBS)的當前股價是多少?

Emergent BioSolutions Inc(EBS)的當前股價是 12.430。

Emergent BioSolutions Inc 的股票代碼是什麼?

Emergent BioSolutions Inc的股票代碼是EBS。

Emergent BioSolutions Inc股票的52週最高點是多少?

Emergent BioSolutions Inc股票的52週最高點是13.410。

Emergent BioSolutions Inc股票的52週最低點是多少?

Emergent BioSolutions Inc股票的52週最低點是4.020。

Emergent BioSolutions Inc的市值是多少?

Emergent BioSolutions Inc的市值是655.06M。

Emergent BioSolutions Inc的淨利潤是多少?

Emergent BioSolutions Inc的淨利潤為-190.60M。

現在Emergent BioSolutions Inc(EBS)的股票是買入、持有還是賣出?

根據分析師評級,Emergent BioSolutions Inc(EBS)的總體評級為買入,目標價格為13.500。

Emergent BioSolutions Inc(EBS)股票的每股收益(EPS TTM)是多少

Emergent BioSolutions Inc(EBS)股票的每股收益(EPS TTM)是1.421。
KeyAI